Corporate ActionJul 16, 2026, 05:26 PM
Tarsier Pharma Plans IPO of 5.56M Shares at $8.00-$10.00
AI Summary
Tarsier Pharma Ltd. filed an amendment to its F-1 registration statement for an initial public offering of 5,555,555 ordinary shares, anticipated to be priced between $8.00 and $10.00 per share. The company plans a 10-for-1 forward stock split prior to closing the offering and has applied to list its shares on the NYSE under "TARX". Tarsier, a late clinical-stage biopharmaceutical company, is developing TRS01 for non-infectious anterior uveitis and uveitic glaucoma, having secured an FDA Special Protocol Assessment for its pivotal Phase 3 trial.
Key Highlights
- Plans initial public offering of 5,555,555 ordinary shares.
- Anticipated IPO price range of $8.00 to $10.00 per share.
- 10-for-1 forward stock split planned before offering closes.
- Underwriter has option for 833,333 additional shares.
- Applied to list ordinary shares on NYSE under symbol "TARX".
- U.S. market for uveitic glaucoma estimated over $5 billion annually.
- Pivotal Phase 3 trial for TRS01 under FDA Special Protocol Assessment.
Price Impact
More from TARX